Vascular Biogenics Ltd. (NASDAQ:VBLT) was the recipient of some unusual options trading on Tuesday. Investors acquired 898 call options on the stock. This is an increase of 1,097% compared to the average daily volume of 75 call options.

Vascular Biogenics (VBLT) opened at $8.25 on Friday. Vascular Biogenics has a fifty-two week low of $3.90 and a fifty-two week high of $9.05. The company has a market capitalization of $245.23, a price-to-earnings ratio of -10.44 and a beta of -3.00.

Several equities analysts have weighed in on the company. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. Zacks Investment Research cut Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Friday, November 24th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Vascular Biogenics in a report on Tuesday, November 21st. Finally, Chardan Capital lifted their price objective on Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, November 6th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. Vascular Biogenics has a consensus rating of “Hold” and an average target price of $15.67.

An institutional investor recently bought a new position in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.08% of Vascular Biogenics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.59% of the company’s stock.

WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.